Apolipoprotein E2 (Arg-136→Gys), a variant of apolipoprotein e associated with late-onset dominance of type III hyperlipoproteinaemia

European Journal of Clinical Investigation

Volumn 26, Issue 1, 1996, Pages 13-23

  Feussner, G ^a,e   Albanese, M ^a   Mann, W A ^b   Valencia, A ^c   Schuster, H ^d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Europaisches Lab F M   (Germany)

^d Franz Volhard Klinik   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apo E2 (Arg 136 Cys); Apolipoprotein E; Dominant mode of inheritance; Dysbetalipoproteinaemia; Type III hyperlipoproteinaemia

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOMINANT INHERITANCE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AMINO ACID SEQUENCE; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; ARGININE; BASE SEQUENCE; CYSTEINE; FEMALE; HEPARIN; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; ISOELECTRIC FOCUSING; LIPOPROTEINS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEDIGREE; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 0030068756     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.83232.x     Document Type: Article

References (65)

1. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
2. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981;20:1033-41.
3. Weisgraber KH, Rall SC Jr, Mahley RW. Human apolipoprotein E heterogeneity. Cysteine arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1982;256:9077-83.
4. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982;257:4171-8.
5. Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA 1982;79:4696-700.
6. 146→Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest 1983;72:1288-97.
7. Weisgraber KH, Rall SC Jr, Innerarity TL, Mahley RW, Kuusi T, Ehnholm C. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1. J Clin Invest 1984;73:1024-33.
8. McLean JW, Elshourbagy NA, Chang DJ, Mahley RW, Taylor JM. Human apolipoprotein E mRNA, cDNA cloning and nucleotide sequencing of a new variant. J Biol Chem 1984;259:6498-504.
9. Havekes L, de Wit E, Gevers Leuven J et al. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum Genet 1986;73:157-63.
10. Wardell MR, Brennan SO, Janus FD, Fraser R, Carrell RW. Apolipoprotein E2-Christchurch (136 Arg→Ser). New variant of apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 1987;80:483-90.
11. Tajima S, Yamamura T, Yamamoto A. Analysis of apolipoprotein E5 gene from a patient with hyperlipoproteinemia. J Biochem (Tokyo) 1988;104:48-52.
12. Tajima S, Yamamura T, Menju M, Yamamoto A. Analysis of apolipoprotein E7 (apolipoprotein E-Suita) gene from a patient with hyperlipoproteinemia. J Biochem (Tokyo) 1989;105:249-53.
13. Rall SC Jr, Newhouse YM, Clarke HRG et al. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3: structure and genetics of an apolipoprotein E3 variant. J Clin Invest 1989;83:1095-101.
14. Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim Biophys Acta 1989;1005:239-44.
15. Wardell MR, Weisgraber KH, Havekes LM, Rall SC Jr. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121 to 127. J Biol Chem 1989;264:21205-10.
16. Van den Maagdenberg AMJM, de Knijff P, Stalenhoef AFH, Gevers Leuven JA, Havekes LM, Frants RR. Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4. Biochem Biophys Res Commun 1989;165:851-7.
17. Smit M, de Knijff P, van der Kooij-Meijs E et al. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2 (lys146→gln) variant results in a dominant mode of inheritance. J Lipid Res 1990;31:45-53.
18. Wardell MR, Rall SC Jr, Brennan SO et al. Apolipoprotein E2-Dunedin (228 Arg→Cys): an apolipoprotein E2 variant with normal receptor-binding activity. J Lipid Res 1990;31:535-43.
19. Mailly F, Xu C-F, Xhignesse M, et al. Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects. J Lipid Res 1991;32:613-20.
20. de Knijff P, van den Maagdenberg AMJM, Stalenhoef AFH et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991;88:643-55.
21. 145→Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J Biol Chem 1991;266:10479-84.
22. 145→Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. J Biol Chem 1992;267:13642-6.
23. van den Maagdenberg AMJM, Weng W, de Bruijn JH et al. Characterization of five new mutants in the carboxy-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. Am J Hum Genet 1993;52:937-46.
24. 112→Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis. Electrophoresis 1993;14:1032-7.
25. Walden CC, Huff MW, Leiter LA, Connelly PW, Hegele RA. Detection of a new apoliprotein-E mutation in type III hyperlipoproteinemia using deoxyribonucleic acid restriction isotyping, J Clin Endocrinol Metab 1994;78:699-704.
26. 136→His): association with mild dyslipidemia and double pre-β very low density lipoproteins. J Lipid Res 1995;36:57-66.
27. Schneider WJ, Kovanen PT, Brown MS et al. Familial dysbetalipoproteinemia: abnormal binding of human fibroblasts and membranes from liver and adrenals of rats, rabbits, and cows. J Clin Invest 1981;68:1075-85.
28. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apolipoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982;257:2518-21.
29. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
30. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th edn. New York: McGraw-Hill Book Co., 1989:1195-213.
31. Brewer HB Jr, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 1983;98:623-40.
32. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433-40.
33. Mahley RW, Innerarity TL, Rail SC Jr, Weisgraber KH, Taylor JM. Apolipoprotein E: genetic variants provide insights into its structure and function. Curr Opin Lipidol 1990;1:87-95.
34. Havel RJ, Eder HA, Bragdon JH The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
35. Luley C, Baumstark MW, Wieland H. Rapid apolipoprotein E phenotyping by immunofixation in agarose. J Lipid Res 1991;32:880-3.
36. Redgrave TG, Roberts DCK, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975;65:42-9.
37. van Meisen A, De Greve Y, Vanderveiken F, Vastesaeger M, Blaton V, Peeters H. A modified method for phenotyping of hyperlipoproteinaemia on agarose electrophoresis. Clin Chim Acta 1974;55:225-34.
38. Innerarity TL, Pitas RE, Mahley RW. Lipoprotein-receptor interactions. Methods Enzymol 1986;129:542-65.
39. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
40. Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA 1985;82:3445 9.
41. Schuster H, Rauh G, Müller S, Keller C, Wolfram G, Zöllner N. Allele-specific and asymmetric polymerase chain reaction amplification in combination: a one step polymerase chain reaction protocol for rapid diagnosis of familial defective apolipoprotein B-100. Anal Biochem 1992;204:22-5.
42. Schuster H, Richter S, Stratmann G, Keller C, Wolfram G, Zöllner N. Identification of a silent point mutation in the LDL-receptor gene by direct DNA sequencing. Klin Wochenschr 1991;69:517-21.
43. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
44. Emi M, Wu LL, Robertson MA et al. Genotyping and sequence analysis of apolipoprotcin E isoforms. Genomics 1988;3:373-9.
45. Feussner G, Wagner A, Kohl B, Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin Investig 1993;71:362-6.
46. Steinmetz A, Jakobs C, Motzny S, Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 1989;9:405-11.
47. Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC Jr. The functional characteristics of human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem 1992;267:1962-8.
48. Ji Z-S, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994;269:13421-8.
49. Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U. Apo E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res 1995;36:517-525.
50. Das HK, McPherson J, Bruns GAP, Karathanasis SK, Breslow JL. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 1985;260:6240-7.
51. Hixson JE, Cox LA, Borenstein S. The baboon apolipoprotein E gene: structure, expansion and linkage with the gene for apolipoprotein C-I. Genomics 1988;2:315-23.
52. Marotti KR, Whitted BE, Castle CK, Polites HG, Melchior GW. Nucleotide sequence of the cynomolgus monkey apolipoprotein E cDNA. Nucleic Acids Res 1989;17:1778.
53. Lee B-R, Miller JM, Yang C-Y et al. Amino acid sequence of rabbit apolipoprotein E. J Lipid Res 1991;32:165-71.
54. McLean JW, Fukazawa C, Taylor JM. Rat apolipoprotein E mRNA: cloning and sequencing of double-stranded cDNA. J Biol Chem 1983;258:8993-9000.
55. Rajavashisth TB, Kaptein JS, Reue KL, Lusis AJ. Evolution of apolipoprotein E: mouse sequence and evidence for an 11-nucleotide ancestral unit. Proc Natl Acad Sci USA 1985;82:8085-9.
56. Matsushima T, Getz GS, Meredith SC. Primary structure of guinea pig apolipoprotein E. Nucleic Acids Res 1990;18:202.
57. Luo C-C, Li W-H, Chan L. Structure and expression of dog apolipoprotein A-I, E, and C-I mRNAs: implication for the evolution and functional constraints of apolipoprotein structure. J Lipid Res 1989;30:1735-46.
58. Davis RW, Pierotti VR, Lauer SJ et al. Lipoproteins in pinnipeds: analysis of a high molecular weight form of apolipoprotein E. J Lipid Res 1991;32:1013-23.
59. Yang Y-W, Chan L, Li W-H. Cloning and sequencing of bovine apolipoprotein E complementary DNA and molecular evolution of apolipoprotein E, C-I, and C-II. J Mol Evol 1991;32:469-75.
60. Schiller M, Edmundson AB. Use of helical wheels to represent the structures of proteins and to identify segments with helical potential. Biophys J 1967;7:121-35.
61. Morrisett JD, Jackson RL, Gotto AM Jr. Lipid-protein interactions in the plasma lipoproteins. Biochim Biophys Acta 1977;472:93-133.
62. Osborne JC Jr, Brewer HB Jr. The plasma lipoproteins. Adv Protein Chem 1977;31:253-337.
63. Feussner G, Wagner A, Ziegler R. Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia. Hum Genet 1993;92:122-6.
64. Utermann G, Vogelberg KH, Steinmetz A et al. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III. Clin Genet 1979;15:37-62.
65. Rall SC Jr, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med 1992;231:653-9.